NeurologyRoche
Roche Reports Phase 3 Results for Fenebrutinib in Relapsing Multiple Sclerosis
BMI
Biotechnology Media Insights
Editorial Team · July 15, 2025
Roche announces Phase 3 FENhance trial results evaluating fenebrutinib, a non-covalent BTK inhibitor, in patients with relapsing multiple sclerosis.
Roche today announced results from the Phase 3 FENhance trials evaluating fenebrutinib in patients with relapsing multiple sclerosis (RMS). The trials demonstrated significant reductions in annualized relapse rates and MRI lesion activity compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.